Availability Analysis of Essential Medicines in the Czech Republic 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Availability of Essential Medicines in the Czech Republic" report to their offering.

The report provides overview of the situation in the Czech Republic. Essential medicines availability gap represents both public health concern and risk of harm to individual patients. Substitute and second line therapies are often less effective, more toxic, or more expensive. Improvisation and the use of less familiar medicines are more likely to lead to medication errors.

Mitigation of shortages and creation of shared contingency supplies puts additional strain on understaffed hospitals, in addition to human toll inflicted by social stress. Drug shortages make it impossible to follow evidence-based practice guidelines, and force decisions to prioritize certain group of people over another.

Public health concerns arise due to inability to prevent and treat contagious diseases such as tuberculosis. Significant resources have to be dedicated to overseeing and managing the situation at government and supranational level.

Of the 427 essential medicines, 311 are registered. Of these, 292 essential medicines showed active marketing in Q3 2016 and 19 were registered but not marketed. 116 (27%) were not registered, and therefore not available, rather than in shortage locally. Availability gap amounts to 135 (32%) essential medicines for both unregistered and not marketed essential medicines.

Key Topics Covered:

I. Analysis and Interpretation

Relevance of unavailability of essential medicines for health care systems

II. Situation in the Czech Republic

- Alimentary tract and metabolism

- Blood and blood forming organs

- Cardiovascular system

- Dermatologicals

- Genito-urinary products and sex hormones

- Hormones for systemic use, excluding sex hormones and insulins

- Antiinfectives for systemic use

- Antineoplastic products

- Musculoskeletal system

- Nervous system

- Antiparasitics

- Respiratory system

- Sensory organs

- Various

III. Significant global drug shortages

- Parenteral nutrition components

- Sterile injectable drugs

- Adulterated heparin

- Sudden price spikes in off-patent prescription drugs

- Antibacterials

- Front-line tuberculosis therapy

- Drugs for the treatment of HIV/AIDS and other antivirals

- Immune sera and immunoglobulins

- Vaccines

- Miltefosin

- Oncology drugs

- Central Nervous System

- Antimalarial drugs

- Pharma Bro: Daraprim (pyrimethamine) and the like

IV. Conclusion

Companies Mentioned

- American Regent

- Aurobindo

- Cipla

- Doctors Without Borders

- GlaxoSmithKline

- Hetero

- Hospira

- Mayo Clinic

- Mylan

- Profounda

- Ranbaxy

- Retrophin Inc.

- Rodelis Therapeutics

- Shunxin Meihua Bio-technical

- TEVA Pharmaceuticals

- Turing Pharmaceuticals

- Valeant Pharmaceuticals International

For more information about this report visit http://www.researchandmarkets.com/research/xrswq6/availability_of

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals